HDL glycoprotein composition and site-specific glycosylation differentiates between clinical groups and affects IL-6 secretion in lipopolysaccharide-stimulated monocytes

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Krishnan, Sridevi ^a   Shimoda, Michiko ^b   Sacchi, Romina ^a   Kailemia, Muchena J ^a   Luxardi, Guillaume ^b   Kaysen, George A ^b   Parikh, Atul N ^c   Ngassam, Viviane N ^c   Johansen, Kirsten ^d   Chertow, Glenn M ^e   Grimes, Barbara ^d   Smilowitz, Jennifer T ^a   Maverakis, Emanual ^b   Lebrilla, Carlito B ^a   Zivkovic, Angela M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GLYCOPEPTIDE; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

DIABETES MELLITUS; GLYCOSYLATION; HEMODIALYSIS; HUMAN; IMMUNOLOGY; INFECTION; ISOLATION AND PURIFICATION; METABOLISM; MONOCYTE; SECRETION (PROCESS);

BIOMARKERS; CYTOKINES; DIABETES MELLITUS; GLYCOPEPTIDES; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; INFECTION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LIPOPROTEINS, HDL; MONOCYTES; RENAL DIALYSIS;

EID: 85015165134     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43728     Document Type: Article

References (39)

1. Toth, P. P. et al. High-density lipoproteins: a consensus statement from the National Lipid Association. Journal of clinical lipidology 7, 484-525, doi: 10.1016/j.jacl.2013.08.001 (2013).
2. Zhu, X. & Parks, J. S. New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr 32, 161-182, doi: 10.1146/annurevnutr- 071811-150709 (2012).
3. Feingold, K. R. & Grunfeld, C. The role of HDL in innate immunity. J Lipid Res 52, 1-3, doi: 10.1194/jlr.E012138 (2011).
4. Andreassen, O. A. et al. Abundant Genetic Overlap between Blood Lipids and Immune-Mediated Diseases Indicates Shared Molecular Genetic Mechanisms. PloS one 10, e0123057, doi: 10.1371/journal.pone.0123057 (2015).
5. van Leeuwen, H. J. et al. The role of high density lipoprotein in sepsis. Neth J Med 59, 102-110, doi: S0300297701001449 [pii] (2001).
6. Levine, D. M., Parker, T. S., Donnelly, T. M., Walsh, A. & Rubin, A. L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 90, 12040-12044 (1993).
7. Munford, R. S., Hall, C. L., Lipton, J. M. & Dietschy, J. M. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest 70, 877-888 (1982).
8. Levels, J. H. et al. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect Immun 73, 2321-2326, doi: 73/4/2321 [pii] 10.1128/IAI.73.4.2321-2326.2005 (2005).
9. Yin, K. et al. Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb 19, 823-836 (2012).
10. De Nardo, D. et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nature immunology 15, 152-160, doi: 10.1038/ni.2784 (2014).
11. Umemoto, T. et al. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 112, 1345-1354, doi: 10.1161/CIRCRESAHA.111.300581 (2013).
12. Eklund, K. K., Niemi, K. & Kovanen, P. T. Immune functions of serum amyloid A. Crit Rev Immunol 32, 335-348 (2012).
13. Grunfeld, C. & Feingold, K. R. HDL and innate immunity: a tale of two apolipoproteins. J Lipid Res 49, 1605-1606, doi: 10.1194/jlr. E800011-JLR200 (2008).
14. Van Lenten, B. J. et al. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 48, 2344-2353, doi: 10.1194/jlr.M700138-JLR200 (2007).
15. Van Lenten, B. J. et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96, 2758-2767, doi: 10.1172/JCI118345 (1995).
16. Kontush, A. & Chapman, M. J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58, 342-374, doi: 58/3/342[pii]10.1124/pr.58.3.1 (2006).
17. Vaisar, T. et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117, 746-756, doi: 10.1172/JCI26206 (2007).
18. Vaisar, T. Proteomics investigations of HDL: challenges and promise. Current vascular pharmacology 10, 410-421 (2012).
19. Alwaili, K. et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821, 405-415, doi: 10.1016/j.bbalip.2011.07.013 (2012).
20. Maverakis, E. et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun 57, 1-13, doi: 10.1016/j.jaut.2014.12.002 (2015).
21. Huang, J. et al. Glycomic analysis of high density lipoprotein shows a highly sialylated particle. J Proteome Res 13, 681-691, doi: 10.1021/pr4012393 (2014).
22. Krishnan, S. et al. Combined HDL proteomic and glycomic profiles in patients at risk for coronary artery disease. J Proteome Res, doi: 10.1021/acs.jproteome.5b00730 (2015).
23. Savinova, O. V., Fillaus, K., Jing, L., Harris, W. S. & Shearer, G. C. Reduced apolipoprotein glycosylation in patients with the metabolic syndrome. PloS one 9, e104833, doi: 10.1371/journal.pone.0104833 (2014).
24. Israili, Z. H., Lyoussi, B., Hernandez-Hernandez, R. & Velasco, M. Metabolic syndrome: treatment of hypertensive patients. American journal of therapeutics 14, 386-402, doi: 10.1097/01.pap.0000249936.05650.0c (2007).
25. Collins, A. J. et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 57, A8, e1-526, doi: 10.1053/j.ajkd.2010.10.007 (2011).
26. Johansen, K. L. et al. Comparison of self-report-based and physical performance-based frailty definitions among patients receiving maintenance hemodialysis. Am J Kidney Dis 64, 600-607, doi: 10.1053/j.ajkd.2014.03.016 (2014).
27. Hong, Q., Lebrilla, C. B., Miyamoto, S. & Ruhaak, L. R. Absolute Quantitation of Immunoglobulin G and Its Glycoforms Using Multiple Reaction Monitoring. Analytical Chemistry 85, 8585-8593, doi: 10.1021/ac4009995 (2013).
28. Schieffer, B. et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110, 3493-3500, doi: 10.1161/01.CIR.0000148135.08582.97 (2004).
29. Tous, M. et al. Manipulation of inflammation modulates hyperlipidemia in apolipoprotein E-deficient mice: a possible role for interleukin-6. Cytokine 34, 224-232, doi: 10.1016/j.cyto.2006.05.007 (2006).
30. Onat, A. et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med 26, 981-988, doi: 10.1111/j.1464-5491.2009.02814.x (2009).
31. Mange, A. et al. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach. PloS one 7, e34107, doi: 10.1371/journal.pone.0034107 (2012).
32. Shao, B. et al. A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects. J Proteome Res 14, 2792-2806, doi: 10.1021/acs.jproteome.5b00060 (2015).
33. Mauger, J. F., Couture, P., Bergeron, N. & Lamarche, B. Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism. J Lipid Res 47, 1212-1218, doi: 10.1194/jlr.M500455-JLR200 (2006).
34. Deighan, C. J., Caslake, M. J., McConnell, M., Boulton-Jones, J. M. & Packard, C. J. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35, 852-862 (2000).
35. Saroha, A., Kumar, S., Chatterjee, B. P. & Das, H. R. Jacalin bound plasma O-glycoproteome and reduced sialylation of alpha 2-HS glycoprotein (A2HSG) in rheumatoid arthritis patients. PloS one 7, e46374, doi: 10.1371/journal.pone.0046374 (2012).
36. Hunt, J. M. & Tuder, R. Alpha 1 anti-trypsin: one protein, many functions. Curr Mol Med 12, 827-835 (2012).
37. Catapano, A. L., Pirillo, A., Bonacina, F. & Norata, G. D. HDL in innate and adaptive immunity. Cardiovasc Res 103, 372-383, doi: 10.1093/cvr/cvu150 (2014).
38. Chiba, T. et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arteriosclerosis, thrombosis, and vascular biology 31, 1326-1332, doi: 10.1161/ATVBAHA.111.226159 (2011).
39. Sarrats, A. et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl 4, 432-448, doi: 10.1002/prca.200900150 (2010).